The
information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to
these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement
and the accompanying base prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted.
Filed
Pursuant to Rule 424(b)(5)
Registration No. 333-232122
Subject
to completion, dated March 11, 2021
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus dated June 25, 2019)
$
MARKER THERAPEUTICS, INC.
Common Stock
|
|
|
$ per share
|
|
|
We are offering $ of shares of our common stock.
Our common stock is listed on The Nasdaq Global Market under
the trading symbol “MRKR.” On March 10, 2021, the last reported sale price of our common stock on The Nasdaq Global
Market was $2.51 per share.
Investing in our common stock involves a high degree of risk.
See “Risk Factors” beginning on page S-4 of this prospectus supplement and in the documents incorporated by reference
into this prospectus supplement and the accompanying prospectus.
|
|
Per Share
|
|
Total
|
Public offering price
|
|
$
|
|
$
|
Underwriting discount(1)
|
|
$
|
|
$
|
Proceeds, before expenses, to Marker Therapeutics, Inc.
|
|
$
|
|
$
|
|
(1)
|
See “Underwriting” beginning on page S-14 of this prospectus supplement for additional information regarding
underwriting compensation.
|
We have granted the underwriters an option for a period of
30 days to purchase up to an additional $ of shares of common stock at the public offering price, less the underwriting
discounts and commissions.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares of common stock
to investors on or about March , 2021.
Piper Sandler
The date of this prospectus supplement
is ,
2021.
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
PROSPECTUS
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is part of a “shelf”
registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, and is in two parts.
The first part is this prospectus supplement, which describes the specific terms of this common stock offering and also adds to
and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The second
part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring
to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus
supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed
prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that
if any statement in one of these documents is inconsistent with a statement in another document having a later date—for example,
a document incorporated by reference in the accompanying prospectus—the statement in the document having the later date modifies
or supersedes the earlier statement.
We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating
risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover,
such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties
and covenants should not be relied on as accurately representing the current state of our affairs.
We have not authorized anyone to provide any
information other than that contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus.
We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer
to purchase, the securities offered by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from
any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. The information
contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein or therein is accurate
only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or of any sale of our common stock. It is important for you to read and consider all information contained in this prospectus
supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your
investment decision. You should also read and consider the information in the documents to which we have referred you in the sections
titled “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” in
this prospectus supplement and in the accompanying prospectus.
We are offering to sell, and seeking offers
to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus
supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law.
Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus
supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus
do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities
offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful
for such person to make such an offer or solicitation.
Unless the context indicates otherwise,
as used in this prospectus supplement and the accompanying prospectus, references to “we,” “us,”
“our,” “the company” and “Marker Therapeutics” refer to Marker Therapeutics, Inc.,
formerly known as TapImmune, Inc., and its subsidiaries. We own various U.S. federal trademark applications and unregistered
trademarks, including our company name. All other trademarks or trade names referred to in this prospectus supplement and the
accompanying prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names
in this prospectus supplement and the accompanying prospectus are referred to without the symbols ® and ™, but such
references should not be construed as any indication that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto.
PROSPECTUS
SUPPLEMENT SUMMARY
This summary highlights selected
information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents we
incorporate by reference. This summary does not contain all of the information you should consider before investing in our
common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully, especially the
risks of investing in our common stock discussed under “Risk Factors” beginning on page S-4 of this prospectus
supplement and under similar headings in our Annual Report on Form 10-K for the year ended December 31, 2020, which is
incorporated by reference in this prospectus supplement, along with our consolidated financial statements and notes to those
consolidated financial statements and the other information incorporated by reference in this prospectus supplement and the
accompanying prospectus, before making an investment decision.
Company Overview
We are a clinical-stage immuno-oncology
company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based
vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates
from our MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells
that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing
two pipelines of product candidates as part of our MultiTAA-specific T cell program: the autologous T cells for the treatment of
lymphoma, multiple myeloma, or MM, and selected solid tumors and the allogeneic T cells for the treatment of acute myeloid leukemia,
or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically engineer the MultiTAA-specific T cell therapies,
we believe that our product candidates are easier and less expensive to manufacture, have lower toxicities than current engineered
chimeric antigen receptor, or CAR-T, and T cell receptor-based therapies and may provide patients with meaningful clinical benefit.
We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors.
We are pursuing post-transplant AML as
the lead indication for our first company-sponsored MultiTAA-specific T cell program. In April 2020, the FDA granted orphan drug
designation to MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant. The MultiTAA-specific T cell
therapy has been well tolerated in an ongoing Phase 1 clinical trial in AML and myelodysplastic syndrome, or MDS, conducted by
our strategic partner Baylor College of Medicine, or BCM. As reported in a recent publication by Lulla et al., 11 of the 17 patients
in the adjuvant disease setting dosed with the MultiTAA-specific T cell therapy after receiving an allogeneic hematopoietic stem
cell transplant, or HSCT, never relapsed [median leukemia-free survival, or LFS, not reached at a median follow-up of 1.9 years],
with 11 of 15 patients remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion
which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year
survival probability of 42%]. Additionally, eight patients were treated for active disease that was resistant to salvage therapy
post-HSCT with a median of five prior lines of therapy (range: four to 10). One of the eight patients crossed over from the adjuvant
group while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after
their first MultiTAA-specific T cell infusion. Two of the eight patients achieved objective responses with one complete response
and one partial response, with six patients continuing with stable disease.
We submitted an investigational new drug,
or IND, application to the United States Food and Drug Administration, or the FDA, to initiate a Phase 2 clinical trial of MultiTAA-specific
T cell therapy, which we refer to as MT-401 (zedenoleucel), in post-allogeneic HSCT patients with AML in both the adjuvant and
active disease setting. The dose administered in this multicenter trial is the approximate flat dose equivalent of the current
maximum tolerated dose from the ongoing Phase 1 trial. In the adjuvant setting, patients will be randomized to either MultiTAA-specific
T cell therapy at approximately 90 days post-transplant versus standard of care observation, while the active disease patients
will receive MT-401 following relapse post-transplant as part of a single-arm group. We expect to complete the safety lead-in portion
of the trial in the first half of 2021. We anticipate that we will initiate the remainder of the Phase 2 trial in the third quarter
of 2021 and complete enrollment of 20 patients in that phase of the trial in the fourth quarter of 2021 in order to report results
from the active disease arm of the trial in the first quarter of 2022. We expect to begin manufacturing MT-401 for the Phase 2
trial at our cGMP manufacturing facility in the third quarter of 2021.
We reported interim data for an
ongoing Phase 1/2 clinical trial of the MultiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma being
conducted by BCM. In this trial, we have observed a clinical benefit correlated with the post-infusion detection of
tumor-reactive T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of
the trial. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of
antigen spreading. To date, we have not observed any cytokine release syndrome or neurotoxicity in this trial.
We
are also evaluating the MultiTAA-specific T cell therapies in a Phase 2 clinical trial for the treatment of breast cancer and
in Phase 1 clinical trials for the treatment of ALL, lymphoma, MM and sarcoma, all of which are being conducted by BCM. As of
December 2020, the MultiTAA-specific T cell therapies have been generally well tolerated by all of the patients enrolled in clinical
trials in hematological and solid tumor indications with no incidents of cytokine release syndrome or neurotoxicity, which are
frequently associated with CAR-T therapies. Our ongoing clinical trials may be also affected by the COVID-19 pandemic. Based on
our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the MultiTAA-specific T cell
therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant in vivo expansion of T cells. We
may initiate additional Phase 2 clinical trials investigating other indications in addition to our planned Phase 2 trial in post-transplant
AML patients.
Pipeline
Our clinical-stage pipeline, including
clinical trials being conducted by BCM and other partners, is set forth below:
Recent Developments
Initiation of Phase 2 Clinical Trial of MT-401 (zedenoleucel)
for the Treatment of Post-Transplant AML
In
January 2021, we announced that the FDA lifted the partial clinical hold on the Phase 2 clinical trial investigating the safety
and efficacy of MT-401 for the treatment of patients with AML post-transplant, permitting us to initiate the trial with the safety
lead-in portion that is expected to enroll approximately six patients. Three patients will be dosed with MT-401 manufactured with
the legacy reagent used in the Phase 1 trial, and three patients will be dosed with MT-401 manufactured using a new reagent from
an alternative supplier. We anticipate using this supplier for clinical and commercial manufacturing of MT-401. We expect to complete
the safety lead-in portion of the trial in the first half of 2021, and we continue to work to identify clinical trial sites.
Corporate Information
We were
incorporated under the laws of the State of Nevada in 1991 under the name “TapImmune, Inc.” and reincorporated in
Delaware in October 2018 under the name “Marker Therapeutics, Inc.” On October 17, 2018, we completed a business
combination with a Delaware corporation that was then known as “Marker Therapeutics, Inc.,” or
Private Marker, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 15,
2018, by and among us, Private Marker and Timberwolf Merger Sub, Inc., a Delaware corporation and a wholly owned
subsidiary of TapImmune, or Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into Private
Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune and the surviving corporation of the
merger. In connection with the merger, we changed our name from “TapImmune, Inc.” to “Marker
Therapeutics, Inc.” and Private Marker changed its name to “Marker Cell Therapy, Inc.” and became our
wholly owned subsidiary. Our principal executive offices are located at 3200 Southwest Freeway, Suite 2240, Houston, Texas
77027, and our telephone number is (713) 400-6400. Our website is located at http://www.markertherapeutics.com. We do
not incorporate by reference into this prospectus supplement the information on, or accessible through, our website. We have
included our website address in this prospectus solely as an inactive textual reference.
The
Offering
Common stock offered by us
|
$ of shares
|
Common stock to be outstanding after this offering
|
shares
|
Option to purchase additional shares of common stock
|
We have granted the underwriters an option for 30 days from the date of this prospectus supplement to purchase up to additional shares of our common stock.
|
Use of Proceeds
|
We estimate that the net proceeds to us in
this offering will be approximately
$ million, or approximately $ million if the underwriters exercise in full their option to purchase additional shares,
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We plan to use the net proceeds from this
offering, together with our existing cash and cash equivalents to fund our current Phase 2 trial of MT-401 in AML, to advance the
development of our MultiTAA therapies into clinical trials in other indications, to fund our manufacturing activities and for working
capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses
or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with
respect to any acquisitions as of the date of this prospectus supplement. See “Use of Proceeds.”
|
Risk Factors
|
You should read the “Risk Factors” section of this prospectus supplement and in the documents incorporated by reference herein for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
|
Nasdaq Global Market symbol
|
“MRKR”
|
The number of shares of our common stock to
be outstanding after this offering is based on 50,731,072 shares of our common stock outstanding as of December 31, 2020 and excludes:
|
·
|
6,001,814 shares of our common stock issuable upon the exercise of
stock options outstanding as of December 31, 2020, at a weighted-average exercise price of $6.22 per share;
|
|
·
|
20,830,000 shares of our common stock issuable upon the exercise of
warrants outstanding as of December 31, 2020, at a weighted-average exercise price of $4.47 per share; and
|
|
·
|
4,685,873 shares of our common stock reserved for future issuance
under our 2020 Equity Incentive Plan.
|
Unless otherwise indicated, all information
in this prospectus supplement assumes no exercise of the outstanding options and warrants described above and no exercise by the
underwriters of their option to purchase additional shares of our common stock.
RISK FACTORS
Investing in our common stock involves
a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and uncertainties
described below together with all other information contained in this prospectus supplement, the accompanying prospectus and in
our filings with the SEC that we have incorporated by reference into this prospectus supplement and the accompanying prospectus.
If any of the following risks actually occurs, our business, prospects, operating results and financial condition could suffer
materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.
Risks Related to this Offering and Ownership of our Common
Stock
We have broad discretion over the use of our cash,
cash equivalents and marketable securities, including the net proceeds we receive in this offering, and may not use them effectively.
Our management has broad discretion to use
our cash and cash equivalents, including the net proceeds we receive in this offering, to fund our operations and could spend these
funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management
to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the
price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations,
we may invest our cash, cash equivalents and marketable securities in a manner that does not produce income or that loses value.
See “Use of Proceeds.”
If you purchase shares of our common stock in this
offering, you will suffer immediate dilution of your investment.
The price of our common stock in this offering
is substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our
common stock in this offering, you will pay a price per share that substantially exceeds our historical net tangible book value
per share after this offering. To the extent outstanding options or warrants are exercised, you will incur further dilution. Based
on the public offering price of $ per share, you will experience immediate dilution of $ per share, representing the difference
between our as adjusted net tangible book value per share after giving effect to this offering and the assumed public offering
price. See “Dilution.”
Investors in this offering may experience future
dilution.
In order to raise additional capital, we may
in the future offer additional shares of our common stock or other securities convertible into, or exchangeable for, our common
stock at prices that may not be the same as the price per share in this offering. We cannot assure you that we will be able to
sell shares of our common stock or other related securities in any other offering at a price per share that is equal to or greater
than the price per share paid by investors in this offering. If the price per share at which we sell additional shares of our common
stock or related securities in future transactions is less than the price per share in this offering, investors who purchase our
common stock in this offering will suffer dilution in their investment.
In addition,
we have a significant number of stock options and warrants exercisable for shares of our common stock outstanding. To the extent
that outstanding stock options or warrants have been or may be exercised, investors purchasing our common stock in this offering
may experience further dilution in the future.
After this offering, our executive officers and
directors and their affiliates, if they choose to act together, will continue to have the ability to significantly influence all
matters submitted to stockholders for approval.
Upon the completion of this offering, our
executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering will
beneficially own a significant percentage of our outstanding common stock. As a result, following this offering, if these stockholders
were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval,
as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence
the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration
of ownership control may delay, defer or prevent a change in control of our company, entrench our management and board of directors,
or impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
An active trading market for our common stock may
not be sustained following this offering.
Although
our common stock is listed on The Nasdaq Global Market, an active trading market for our shares may not be sustained. If an active
market for our common stock does not continue, it may be difficult for you to sell your shares, including shares you may purchase
in this offering, without depressing the market price for the shares or sell your shares at all. Any inactive trading market for
our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair
our ability to acquire other companies or technologies by using our shares as consideration.
A significant portion of our total outstanding shares
of common stock are restricted from immediate resale but may be sold into the market in the near future, which could cause the
market price of our common stock to drop significantly, even if our business is performing well.
Sales of a substantial number of shares of our common stock
in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in
the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.
Upon the completion of this offering, we will have outstanding shares
of our common stock beneficially owned by our officers, directors and their affiliates that are restricted as a result of lock-up agreements for
a period of 90 days after the date of this prospectus supplement. However, all of the shares of our common stock sold in this offering
and the other shares of our common stock outstanding prior to this offering will not be subject to lock-up agreements
with the underwriters and, except to the extent such shares of our common stock are held by our affiliates, will be freely tradable.
The market price of our common stock could decline as a result of sales by our stockholders in the market following completion
of this offering or the perception that these sales could occur.
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus supplement, the accompanying prospectus and
the documents incorporated by reference herein and therein contain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act. These are based on our management’s current beliefs, expectations and assumptions about future events,
conditions and results and on information currently available to us. Discussions containing these forward-looking statements may
be found, among other places, in the sections titled “Business,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” contained in the documents incorporated by reference
herein.
Any statements in this prospectus supplement or the accompanying
prospectus, or incorporated herein and therein, about our expectations, beliefs, plans, objectives, assumptions or future events
or performance are not historical facts and are forward-looking statements. All statements other than statements of historical
fact could be deemed forward looking, including, but not limited to, statements regarding:
|
·
|
the timing, progress and results of clinical trials of MultiTAA-specific T cell therapies and our other product candidates,
including statements regarding the timing of initiation and completion of preclinical studies or clinical trials or related preparatory
work, the period during which the results of the trials will become available and our research and development programs;
|
|
·
|
the timing of any submission of filings for regulatory approval of product candidates and our ability to obtain and maintain
regulatory approvals for product candidates for any indication;
|
|
·
|
our ability to successfully commercialize product candidates;
|
|
·
|
our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates;
|
|
·
|
our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility
of product candidates, if approved for commercial use;
|
|
·
|
our manufacturing capabilities and strategy, including the ease, scalability and commercial viability of our manufacturing
methods and processes;
|
|
·
|
our expectations regarding the scope of any approved indications for product candidates;
|
|
·
|
the potential benefits of and our ability to maintain our relationships and collaborations with the Baylor College of Medicine
and other potential collaboration or strategic relationships;
|
|
·
|
our ability to use the MultiTAA-specific T cell platform to develop future product candidates;
|
|
·
|
our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain
additional funding;
|
|
·
|
our ability to identify, recruit and retain key personnel;
|
|
·
|
our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;
|
|
·
|
our financial performance;
|
|
·
|
our competitive position and the development of and projections relating to our competitors or our industry;
|
|
·
|
our expected uses of proceeds from this offering; and
|
|
·
|
the impact of laws and regulations.
|
In some cases, you can identify forward-looking statements by
the words “may,” “might,” “can,” “will,” “to be,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,”
“likely,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology
intended to identify statements about the future, although not all forward-looking statements contain these words. These statements
involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements.
You should refer to the section titled “Risk
Factors” contained in this prospectus supplement, the accompanying prospectus and under similar headings in other
documents that are incorporated by reference herein and therein, for a discussion of important factors that may cause our
actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks,
uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking
statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and
therein will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore,
if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by
us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.
Except as required by law, we assume no obligation to update
these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring
after the date of this prospectus supplement, even if new information becomes available in the future.
You should carefully read this prospectus supplement, the accompanying
prospectus and the information incorporated herein and therein by reference, as described in the section titled “Incorporation
of Certain Information by Reference,” completely and with the understanding that our actual future results may be materially
different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
USE OF PROCEEDS
We estimate that the net proceeds to us in
this offering will be approximately $ million, or approximately $ million if the underwriters exercise in full their option
to purchase additional shares, after deducting estimated underwriting expenses and commissions and estimated offering expenses
payable by us.
We intend to use the net proceeds from this
offering, together with our cash and cash equivalents, to fund our Phase 2 trial of MT-401 in AML, to advance the development of
our MultiTAA therapies into clinical trials in other indications, to fund our manufacturing activities and for working capital
and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies
that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any
acquisitions as of the date of this prospectus supplement.
This expected use of our net proceeds from
this offering represents our intentions based upon our current plans and business conditions, which could change in the future
as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending
on numerous factors, including the progress of our product candidate development, the status of and results from clinical trials,
as well as any collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs.
As a result, our management will retain broad
discretion over the allocation of the net proceeds from this offering, and investors will be relying on the judgment of our management
regarding the application of the net proceeds from this offering. The timing and amount of our actual expenditures will be based
on many factors, including cash flows from operations and the anticipated growth of our business. Pending these uses, we expect
to invest the net proceeds in investment-grade, interest-bearing bonds.
Based on the planned use of proceeds
described above, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents,
will be sufficient to enable us to fund our operating expenses and capital expenditure requirements
into
. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital
resources sooner than we currently expect.
DILUTION
If you invest in our common stock in
this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering
price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this
offering.
Our historical net tangible book value
as of December 31, 2020 was $27.3 million, or $0.54 per share of common stock. Historical net tangible book value per share represents
the amount of our total tangible assets less total liabilities, divided by the 50,731,072 shares of our common stock outstanding
on December 31, 2020.
After giving effect to the
issuance and sale of shares of our common stock in this offering, after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net
tangible book value as of December 31, 2020 would have been $ million, or
$ per share. This represents an immediate increase of $ in the as adjusted
net tangible book value per share to existing stockholders and immediate dilution of $ in the as adjusted net tangible
book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is
determined by subtracting as adjusted net tangible book value per share after this offering from the public offering price
per share paid by new investors. The following table illustrates this per share dilution to the new investors purchasing
shares of our common stock in this offering without giving effect to any exercise by the underwriters of their option to
purchase additional shares:
Public offering price per share
|
|
|
|
|
|
$
|
|
|
Historical net tangible book value per share as of December 31, 2020
|
|
$
|
0.54
|
|
|
|
|
|
Increase in as adjusted net tangible book value per share attributable to this offering
|
|
|
|
|
|
|
|
|
As adjusted net tangible book value per share after this offering
|
|
|
|
|
|
|
|
|
Dilution per share to new investors in this offering
|
|
|
|
|
|
$
|
|
|
If the underwriters exercise in full
their option to purchase additional shares, based on the public offering price of $ per share, the as adjusted net tangible
book value will increase to $ per share, representing an immediate increase to existing stockholders of $ per share and
an immediate dilution of $ per share to new investors.
The information discussed above is based on
50,731,072 shares of our common stock outstanding as of December 31, 2020 and excludes:
|
·
|
6,001,814 shares of our common stock issuable upon the exercise of
stock options outstanding as of December 31, 2020, at a weighted-average exercise price of $6.22 per share;
|
|
·
|
20,830,000 shares of our common stock issuable upon the exercise of
warrants outstanding as of December 31, 2020, at a weighted-average exercise price of $4.47 per share; and
|
|
·
|
4,685,873 shares of our common stock reserved for future issuance
under our 2020 Equity Incentive Plan.
|
To the extent that outstanding options
or warrants are exercised or we issue additional options, warrants or shares of our common stock in the future, there will be further
dilution to investors purchasing common stock in this offering.
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
TO NON-U.S. HOLDERS OF OUR COMMON STOCK
The following is a summary of the material
U.S. federal income tax consequences to non-U.S. holders (as defined below) of the acquisition, ownership and disposition of our
common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal income
tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment
income, the alternative minimum tax or the special tax accounting rules under Section 451(b) of the Code, and does not address
any estate or gift tax consequences or any tax consequences arising under any state, local or foreign tax laws, or any other U.S.
federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, and applicable Treasury
Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the Internal
Revenue Service, or IRS, all as in effect as of the date hereof. These authorities are subject to differing interpretations and
may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We
have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary,
and there can be no assurance that the IRS or a court will agree with such statements and conclusions.
This discussion is limited to non-U.S.
holders who purchase our common stock pursuant to this offering and who hold our common stock as a “capital asset”
within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all
of the U.S. federal income tax consequences that may be relevant to a particular holder in light of such holder’s particular
circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject
to special rules under the U.S. federal income tax laws, including:
|
·
|
certain former citizens or long-term residents of the United States;
|
|
·
|
“controlled foreign corporations;”
|
|
·
|
“passive foreign investment companies;”
|
|
·
|
corporations that accumulate earnings to avoid U.S. federal income
tax;
|
|
·
|
banks, financial institutions, investment funds, insurance companies,
brokers, dealers or traders in securities;
|
|
·
|
tax-exempt organizations and governmental organizations;
|
|
·
|
tax-qualified retirement plans;
|
|
·
|
“qualified foreign pension funds” as defined in Section
897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds;
|
|
·
|
persons that own, or have owned, actually or constructively, more
than 5% of our common stock at any time;
|
|
·
|
persons who have elected to mark securities to market; and
|
|
·
|
persons holding our common stock as part of a hedging or conversion
transaction or straddle, or a constructive sale, or other risk reduction strategy or integrated investment.
|
If an entity or arrangement that is classified
as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner
in the partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding
our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal
income tax consequences to them of holding and disposing of our common stock.
THIS DISCUSSION IS FOR INFORMATIONAL
PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL
INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING
UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS.
Definition of Non-U.S. Holder
For purposes of this discussion, the term
“non-U.S. holder” means any beneficial owner of our common stock that is not a “U.S. person” or a partnership
(including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any person
that, for U.S. federal income tax purposes, is or is treated as any of the following:
|
·
|
an individual who is a citizen or resident of the United States;
|
|
·
|
a corporation (or entity treated as a corporation for U.S. federal
income tax purposes) created or organized under the laws of the United States, any state thereof or the District of Columbia;
|
|
·
|
an estate, the income of which is subject to U.S. federal income tax
regardless of its source; or
|
|
·
|
a trust (1) whose administration is subject to the primary supervision
of a U.S. court and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust
or (2) that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.
|
Distributions on Our Common Stock
We have not paid dividends on our common
stock and do not anticipate paying dividends on our common stock for the foreseeable future. However, if we make cash or other
property distributions on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to
the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts
not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against
and reduce a holder’s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the
sale or other disposition of our common stock and will be treated as described under the section titled “—Gain on Disposition
of Our Common Stock” below.
Subject to the discussions below regarding
effectively connected income, backup withholding and Sections 1471 through 1474 of the Code (commonly referred to as FATCA), dividends
paid to a non-U.S. holder generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the
dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a non-U.S.
holder must furnish us or our paying agent with a valid IRS Form W-8BEN or IRS Form W-8BEN-E (or applicable successor form) and
satisfy applicable certification and other requirements. This certification must be provided to us or our paying agent before the
payment of dividends and must be updated periodically. If the non-U.S. holder holds the stock through a financial institution or
other agent acting on the non-U.S. holder’s behalf, the non-U.S. holder will be required to provide appropriate documentation
to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other
intermediaries.
If a non-U.S. holder holds our common stock
in connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are effectively
connected with such holder’s U.S. trade or business (and are attributable to such holder’s permanent establishment
in the United States if required by an applicable tax treaty), the non-U.S. holder will be exempt from U.S. federal withholding
tax. To claim the exemption, the non-U.S. holder must generally furnish a valid IRS Form W-8ECI (or applicable successor form)
to us or our paying agent. However, any such effectively connected dividends paid on our common stock generally will be subject
to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder
were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to an additional branch
profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings
and profits for the taxable year, as adjusted for certain items. Non-U.S. holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules.
Non-U.S. holders that do not provide the
required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts
withheld by timely filing an appropriate claim for refund with the IRS.
Gain on Disposition of Our Common Stock
Subject to the discussions below regarding
backup withholding and FATCA, a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized on
the sale or other disposition of our common stock, unless:
|
·
|
the gain is effectively connected with the non-U.S. holder’s
conduct of a trade or business in the United States, and if required by an applicable income tax treaty, is attributable to a permanent
establishment maintained by the non-U.S. holder in the United States;
|
|
·
|
the non-U.S. holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or
|
|
·
|
our common stock constitutes a “United States real property
interest,” or USRPI by reason of our status as a United States real property holding corporation, or USRPHC, for U.S. federal
income tax purposes at any time within the shorter of the five-year period preceding the disposition or the non-U.S. holder’s
holding period for our common stock.
|
The determination of whether we are a USRPHC
depends on the fair market value of our USRPIs relative to the fair market value of worldwide real property interests and our other
assets used or held for use in a trade or business. We believe that we are not currently and do not anticipate becoming a USRPHC
for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC. Even if we
are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our common stock by a non-U.S. holder
will not be subject to U.S. federal income tax if our common stock is “regularly traded” (as defined by applicable
Treasury Regulations) on an established securities market, and such non-U.S. holder owned, actually and constructively, 5% or less
of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition
or the non-U.S. holder’s holding period. Prospective investors are encouraged to consult their own tax advisors regarding
the possible consequences to them if we are, or were to become, a USRPHC.
Gain described in the first bullet point
above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in
the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may
be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of
its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second
bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable
income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident
of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such
losses. Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different
rules.
Information Reporting and Backup Withholding
Annual reports are required to be filed
with the IRS and provided to each non-U.S. holder indicating the amount of distributions on our common stock paid to such holder
and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply regardless
of whether such distributions constitute dividends and even if no withholding was required. This information also may be made available
under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established.
Backup withholding, currently at a 24% rate, generally will not apply to payments to a non-U.S. holder of dividends on or the gross
proceeds of a disposition of our common stock provided the non-U.S. holder furnishes the required certification for its non-U.S.
status, such as by providing a valid IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-8ECI, or certain other requirements are met.
Backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person who is not
an exempt recipient.
Backup withholding is not an additional
tax. If any amount is withheld under the backup withholding rules, the non-U.S. holder should consult with a U.S. tax advisor regarding
the possibility of and procedure for obtaining a refund or a credit against the non-U.S. holder’s U.S. federal income tax
liability, if any.
FATCA
FATCA imposes a U.S. federal
withholding tax of 30% on certain payments made to a “foreign financial institution” (as specially defined under
these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to
collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such
institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are
foreign entities with U.S. owners) or an exemption applies. FATCA also generally will impose a U.S. federal withholding tax
of 30% on certain payments made to a non-financial foreign entity unless such entity provides the withholding agent a
certification identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental
agreement between the United States and an applicable foreign country may modify these requirements. Under certain
circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends
paid on our common stock. Under applicable Treasury Regulations and administrative guidance, withholding under FATCA would
have applied to payments of gross proceeds from the sale or other disposition of stock on or after January 1, 2019, but under
proposed regulations (the preamble to which specifies that taxpayers are permitted to rely on such proposed regulations
pending finalization), no withholding would apply with respect to payments of gross proceeds.
Prospective investors are encouraged to consult with their own
tax advisors regarding the possible implications of this legislation on their investment in our common stock.
UNDERWRITING
We are offering the shares of common
stock described in this prospectus supplement through Piper Sandler & Co. as book-running manager. We have entered into
an underwriting agreement with Piper Sandler & Co., as representative of the several underwriters named below. Subject
to the terms and conditions set forth in the underwriting agreement, we have agreed to sell to the underwriters, and each of the
underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of our common stock listed opposite
its name below.
Underwriter
|
|
Number of Shares
|
Piper Sandler & Co.
|
|
|
|
|
|
Total
|
|
|
Option to Purchase Additional Shares
We have granted the underwriters an
option to buy up to additional shares of common stock from us to cover over-allotments, if any. The underwriters may exercise this
option at any time and from time to time during the 30-day period from the date of this prospectus supplement. If any
additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on
which the shares are being offered.
Discounts and Commissions
The underwriters have advised us that
they propose to offer the common stock directly to the public at the offering price set forth on the cover page of this prospectus
supplement. The underwriters propose to offer the shares to certain dealers at the same price less a concession of not more than
$ per share. After the offering, these figures may be changed by the underwriters.
The underwriting fee is equal to the
public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The following
table shows the per share and total underwriting discount to be paid by the underwriters in connection with this offering, assuming
either no exercise and full exercise of the option to purchase additional shares:
|
|
|
|
|
Total
|
|
|
|
Per Share
|
|
|
Without Option
|
|
|
With Option
|
|
Public offering price
|
|
$
|
|
|
|
|
|
|
|
|
|
|
Underwriting discounts and commissions
|
|
$
|
|
|
|
|
|
|
|
|
|
|
Proceeds, before expenses, to us
|
|
$
|
|
|
|
|
|
|
|
|
|
|
We estimate that the total fees and
expenses payable by us, excluding underwriting discount, will be approximately $ . We have also agreed to reimburse the underwriters
for certain expenses incurred by them in connection with the offering.
Indemnification of Underwriters
We have agreed to indemnify the underwriters
against certain liabilities, including liabilities under the Securities Act, or to contribute to payments that the underwriters
may be required to make in respect of those liabilities.
No Sales of Similar Securities
We and all of our directors and executive
officers have agreed, subject to certain exceptions, that, without the prior written consent of Piper Sandler & Co. on
behalf of the underwriters, we and they will not, or publicly disclose an intention to, during the period ending 90 days after
the date of this prospectus supplement, in the case of our directors and officers, and 45 days with respect to certain affiliated
funds (the “restricted period”):
|
•
|
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
|
|
•
|
file any registration statement with the Securities and Exchange Commission relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or
|
|
•
|
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock;
|
whether any such transaction described
above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such
person agrees that, without the prior written consent of Piper Sandler & Co. on behalf of the underwriters, we or such
other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration
of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock.
Piper Sandler & Co., in its
sole discretion, may release the common stock and other securities subject to the lock-up agreements described above
in whole or in part at any time.
Listing
Our common stock is listed on The Nasdaq
Global Market under the symbol “MRKR.”
Price Stabilization, Short Positions
and Penalty Bids
To facilitate the offering, the underwriters
may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock during and after the offering.
Specifically, the underwriters may over-allot or otherwise create a short position in the common stock for their own account by
selling more shares of common stock than we have sold to them. Short sales involve the sale by the underwriters of a greater number
of shares than the underwriters are required to purchase in the offering. The underwriters may close out any short position by
either exercising their option to purchase additional shares or purchasing shares in the open market.
In addition, the underwriters may stabilize
or maintain the price of the common stock by bidding for or purchasing shares of common stock in the open market and may impose
penalty bids. If penalty bids are imposed, selling concessions allowed to syndicate members or other broker-dealers participating
in the offering are reclaimed if shares of common stock previously distributed in the offering are repurchased, whether in connection
with stabilization transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price
of the common stock at a level above that which might otherwise prevail in the open market. The imposition of a penalty bid may
also affect the price of the common stock to the extent that it discourages resales of the common stock. The magnitude or effect
of any stabilization or other transactions is uncertain. These transactions may be effected on The Nasdaq Global Market or otherwise
and, if commenced, may be discontinued at any time. The underwriters may also engage in passive market making transactions in our
common stock. Passive market making consists of displaying bids on The Nasdaq Global Market limited by the prices of independent
market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation M promulgated by
the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive
market making may stabilize the market price of the common stock at a level above that which might otherwise prevail in the open
market and, if commenced, may be discontinued at any time.
Electronic Distribution
This prospectus supplement and the
accompanying base prospectus in electronic format may be made available on the web sites maintained by one or more of the underwriters
and the underwriters may distribute prospectuses and prospectus supplements electronically.
Affiliations
From time to time in the ordinary course
of its businesses, the underwriters and certain of their affiliates have engaged, and may in the future engage, in commercial banking
or investment banking transactions with us and our affiliates.
Selling Restrictions
European Economic Area and the United
Kingdom
In relation to each Member State of
the European Economic Area and the United Kingdom (each, a “Relevant State”), no securities have been offered or will
be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to
the securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another
Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation,
except that offers of securities may be made to the public in that Relevant State at any time under the following exemptions under
the Prospectus Regulation:
|
(a)
|
to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
|
|
(b)
|
to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives; or
|
|
(c)
|
in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
|
provided that no such offer of shares
shall require us or any of our representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement
a prospectus pursuant to Article 23 of the Prospectus Regulation.
For the purposes of this provision,
the expression an “offer to the public” in relation to any shares in any Relevant State means the communication in
any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor
to decide to purchase any shares, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (as amended).
United Kingdom
Each underwriter has represented and
agreed that:
|
(a)
|
it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the “FSMA”)) received by it in connection with the issue or sale of the shares of our common stock in circumstances in which Section 21(1) of the FSMA does not apply to us; and
|
|
(b)
|
it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or otherwise involving the United Kingdom.
|
Canada
The shares of common stock may be sold
only to purchasers purchasing as principal that are both “accredited investors” as defined in National Instrument 45-106 Prospectus
and Registration Exemptions and “permitted clients” as defined in National Instrument 31-103 Registration
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock must be made in accordance
with an exemption from the prospectus requirements and in compliance with the registration requirements of applicable securities
laws.
Germany
Each person who is in possession of
this prospectus is aware of the fact that no German securities prospectus (wertpapierprospekt) within the meaning of the German
Securities Prospectus Act (Wertpapier-prospektgesetz, or the Act) of the Federal Republic of Germany has been or will be published
with respect to the shares of our common stock. In particular, each underwriter has represented that it has not engaged and has
agreed that it will not engage in a public offering in the Federal Republic of Germany within the meaning of the Act with respect
to any of the shares of our common stock otherwise than in accordance with the Act and all other applicable legal and regulatory
requirements.
Hong Kong
The shares of common stock may not
be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer
to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii) to “professional investors”
within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (iii) in
other circumstances which do not result in the document being a “prospectus” within the meaning of the Companies Ordinance
(Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares may be issued or may be in the
possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of
Hong Kong) other than with respect to the shares of common stock which are or are intended to be disposed of only to persons outside
Hong Kong or only to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap. 571,
Laws of Hong Kong) and any rules made thereunder.
Singapore
This prospectus supplement has
not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of
common stock may not be circulated or distributed, nor may the shares of common stock be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than
(i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the
“SFA”), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to
Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to
compliance with conditions set forth in the SFA.
Where the shares of common stock are
subscribed or purchased under Section 275 of the SFA by a relevant person which is:
|
(a)
|
a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
|
|
(b)
|
a trust (where the trustee is not an accredited investor) whose sole purpose is to hold
investments and each beneficiary of the trust is an individual who is an accredited investor, shares, debentures and units of shares
and debentures of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not
be transferred within six months after that corporation or that trust has acquired the shares of common stock pursuant to an offer
made under Section 275 of the SFA except:
|
|
(a)
|
to an institutional investor (for corporations, under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section 275 of the SFA;
|
|
(b)
|
where no consideration is or will be given for the transfer; or
|
|
(c)
|
where the transfer is by operation of law.
|
Solely for the purposes of its obligations
pursuant to section 309B(1)(a) and 309B(1)(c) of the SFA and the Securities and Futures (Capital Markets Products) Regulations
2018 of Singapore (the “CMP Regulations 2018”), the issuer has determined, and hereby notifies all relevant persons
(as defined in Section 309A(1) of the SFA), that the shares are “prescribed capital markets products” (as defined
in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale
of Investment Products; and MAS notice FAA-N16: Notice on Recommendations on Investment Products).
Switzerland
The shares of common stock may not
be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the “SIX”) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the shares of common stock or the
offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document nor any other
offering or marketing material relating to the offering, or the shares of common stock have been or will be filed with or approved
by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of the shares of common stock
will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of the shares of common stock
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (“CISA”). Accordingly,
no public distribution, offering or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution
to any non-qualified investor, as defined in CISA, its implementing ordinances and notices, shall be undertaken in or
from Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does
not extend to acquirers of the shares of common stock.
United Arab Emirates
This offering has not been
approved or licensed by the Central Bank of the United Arab Emirates (the “UAE”), Securities and Commodities
Authority of the UAE and/or any other relevant licensing authority in the UAE including any licensing authority incorporated
under the laws and regulations of any of the free zones established and operating in the territory of the UAE, in particular
the Dubai Financial Services Authority (“DFSA”), a regulatory authority of the Dubai International Financial
Centre (“DIFC”). The offering does not constitute a public offer of securities in the UAE, DIFC and/or any other
free zone in accordance with the Commercial Companies Law, Federal Law No 8 of 1984 (as amended), DFSA Offered Securities
Rules and NASDAQ Dubai Listing Rules, accordingly, or otherwise. The shares of common stock may not be offered to the public
in the UAE and/or any of the free zones.
The shares of common stock may be offered
and issued only to a limited number of investors in the UAE or any of its free zones who qualify as sophisticated investors under
the relevant laws and regulations of the UAE or the free zone concerned.
France
This prospectus supplement (including
any amendment, supplement or replacement thereto) is not being distributed in the context of a public offering in France within
the meaning of Article L. 411-1 of the French Monetary and Financial Code (Code monétaire et financier).
This prospectus supplement has not
been and will not be submitted to the French Autorité des marchés financiers (the “AMF”) for approval
in France and accordingly may not and will not be distributed to the public in France.
Pursuant to Article 211-3 of
the AMF General Regulation, French residents are hereby informed that:
|
1.
|
the transaction does not require a prospectus to be submitted for approval to the AMF;
|
|
2.
|
persons or entities referred to in Point 2°, Section II of Article L.411-2 of the Monetary and Financial Code may take part in the transaction solely for their own account, as provided in Articles D. 411-1, D. 734-1, D. 744-1, D. 754-1 and D. 764-1 of the Monetary and Financial Code; and
|
|
3.
|
the financial instruments thus acquired cannot be distributed directly or indirectly to the public otherwise than in accordance with Articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the Monetary and Financial Code.
|
This prospectus supplement is not to be further distributed
or reproduced (in whole or in part) in France by the recipients of this prospectus. This prospectus supplement has been distributed
on the understanding that such recipients will only participate in the issue or sale of our common stock for their own account
and undertake not to transfer, directly or indirectly, our common stock to the public in France, other than in compliance with
all applicable laws and regulations and in particular with Articles L. 411-1 and L. 411-2 of the French
Monetary and Financial Code.
LEGAL MATTERS
The validity of the shares of common stock
offered hereby will be passed upon for us by Cooley LLP, New York, New York. DLA Piper LLP, New York, New York, is representing
the underwriters in connection with this offering.
EXPERTS
Marcum LLP, an independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the
year ended December 31, 2020, as set forth in their report, which includes an explanatory paragraph as to the Company’s
ability to continue as a going concern, dated March 9, 2021, which is incorporated by reference in this prospectus supplement
and elsewhere in the registration statement. Our consolidated financial statements are incorporated by reference in reliance
on Marcum LLP’s report, given on the authority of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus supplement and the accompanying
prospectus are part of the registration statement on Form S-3 we filed with the SEC under the Securities Act
and do not contain all of the information set forth or incorporated by reference in the registration statement and the exhibits
to the registration statement. For further information with respect to us and the securities we are offering under this prospectus
supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as
a part of the registration statement. You should rely only on the information contained in this prospectus supplement and the accompanying
prospectus or incorporated by reference herein and therein. We have not authorized anyone else to provide you with different information.
We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information
in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectus supplement, regardless
of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectus supplement.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at
http://www.sec.gov.
Copies of certain information filed by us
with the SEC are also available on our website at http://www.markertherapeutics.com. Information contained in or accessible
through our website does not constitute a part of this prospectus supplement and is not incorporated by reference in this prospectus
supplement.
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
The SEC allows us to “incorporate by reference”
information into this prospectus supplement, which means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus
supplement is 001-37939. The documents incorporated by reference into this prospectus supplement contain important information
that you should read about us.
The following documents are incorporated by reference into this
document:
|
·
|
our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 9, 2021; and
|
|
·
|
the description of our common stock set forth in the registration statement on Form 8-A registering our common stock under
Section 12 of the Exchange Act, which was filed with the SEC on November 3, 2016, including any amendments or reports filed for
purposes of updating such description.
|
We also incorporate by reference into this prospectus supplement
all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that
are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
(i) after the date of the initial filing of the registration statement of which this prospectus supplement forms a part and prior
to effectiveness of the registration statement, or (ii) after the date of this prospectus supplement but prior to the termination
of the offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K, as well as proxy statements.
We will provide to each person, including any beneficial owner,
to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are
incorporated by reference into this prospectus supplement and the accompanying prospectus but not delivered with the prospectus,
including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents
to Marker Therapeutics, Inc., Attn: Corporate Secretary, 3200 Southwest Freeway, Suite 2500, Houston, Texas 77027.
Any statement contained in this prospectus supplement or contained
in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be modified
or superseded to the extent that a statement contained in this prospectus supplement or any subsequently filed supplement to the
accompanying prospectus, or document deemed to be incorporated by reference into this prospectus supplement, modifies or supersedes
such statement.
The information in this
prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to
sell these securities, and it is not soliciting offers to buy these securities in any state where such offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED JUNE 14, 2019
PROSPECTUS
$200,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
From time to time, we may offer and sell up
to $200,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities
as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including
any applicable anti-dilution provisions.
This prospectus provides a general description
of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these
offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained
in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.
This prospectus may not be used to consummate
a sale of any securities unless accompanied by a prospectus supplement.
We will sell these securities directly to investors,
through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional
information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus
and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect
to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts
or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net
proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.
Our common stock is traded on the Nasdaq Capital
Market under the symbol “MRKR.” On June 13, 2019, the last reported sale price of our common stock was $6.10 per share.
The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital
Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.
Investing in our securities involves
a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors”
contained in the applicable prospectus supplement and any related free writing prospectus we have authorized for use in connection
with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus
as described on page 5 of this prospectus.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL
OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this prospectus is
, 2019.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is a part of a registration
statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration
process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in
one or more offerings up to a total aggregate offering price of $200,000,000. This prospectus provides you with a general description
of the securities we may offer.
Each time we sell securities under this prospectus,
we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings.
The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus.
You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the
information incorporated herein by reference as described under the heading “Incorporation of Certain Information by Reference,”
before investing in any of the securities offered.
THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE
A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
Neither we, nor any agent, underwriter or
dealer has authorized any person to give any information or to make any representation other than those contained or incorporated
by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on
behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free
writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing
prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom
it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information
contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date
subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct
on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus
supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.
This prospectus and the information incorporated
herein by reference contain summaries of certain provisions contained in some of the documents described herein, but reference
is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.
Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits
to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the heading “Where You Can Find More Information.”
SUMMARY
This summary highlights selected information
from this prospectus and does not contain all of the information that you need to consider in making your investment decision.
You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus,
including the risks of investing in our securities discussed under the heading “Risk Factors” contained in the applicable
prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus,
including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is
a part, before making your investment decision.
Unless the context indicates otherwise, as
used in this prospectus, unless the context otherwise requires, references to "we," "us," "our,"
"the company" and "Marker Therapeutics" refer to Marker Therapeutics, Inc., formerly known as TapImmune,
Inc., and its subsidiaries. We own various U.S. federal trademark applications and unregistered trademarks, including our company
name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and ™, but such
references should not be construed as any indication that their respective owners will not assert, to the fullest extent under
applicable law, their rights thereto.
Company Overview
Overview
We are a clinical-stage immuno-oncology company
specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines
for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our
MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize
tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells
are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. We are advancing two MultiTAA T
cell pipelines: our autologous T cells for the treatment of lymphoma, multiple myeloma and selected solid tumors and our allogeneic
T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically
engineer our MultiTAA therapies, we believe that our product candidates are easier and less expensive to manufacture, with reduced
toxicities, than current engineered CAR-T and T cell receptor-based therapies, and may provide patients with meaningful clinical
benefit. We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors,
as well as PolyStart, a proprietary nucleic acid-based antigen expression technology designed to improve the ability of the immune
system to recognize and destroy diseased cells.
We are pursuing post-transplant AML as the
lead indication for our MultiTAA program. Our MultiTAA therapy was well tolerated in our recent Phase 1 clinical trial, with no
drug-related serious adverse events. Eleven of the thirteen patients in the adjuvant disease setting dosed with our MultiTAA therapy
after receiving an allogeneic stem cell transplant survived, ranging from 6 weeks to 2.5 years post-infusion as of March 2019,
with nine of these patients in continuing complete remission. As of March 2019, survival of the six patients with active disease
ranged from 4 to 21 months, as compared to a historical survival rate of 4 months for patients who receive the standard of care
post-transplant. We intend to submit an investigational new drug application to the United States Food and Drug Administration
in the third quarter of 2019 to initiate a Phase 2 clinical trial in post-allogeneic hematopoietic stem cell transplant patients
with AML in both the adjuvant and active disease setting.
We are also evaluating our MultiTAA therapy
in a Phase 2 clinical trial for the treatment of breast cancer and in Phase 1 clinical trials for the treatment of ALL, lymphoma,
multiple myeloma, pancreatic cancer and sarcoma. As of March 2019, our MultiTAA therapy has been well tolerated in all clinical
trials in hematological and solid tumor indications with no drug-related serious adverse events, including cytokine release syndrome
or neurotoxicity. In our clinical trials in lymphoma, ALL and multiple myeloma, we observed that our MultiTAA therapies have shown
the potential to mediate a meaningful anti-tumor effect, as well as significant in vivo expansion of T cells. We may initiate
additional Phase 2 clinical trials in other indications in 2019 in addition to our planned Phase 2 trial in post-transplant AML
patients. We plan to report additional interim data from an ongoing Phase 1/2 clinical trial in pancreatic cancer in the third
quarter of 2019.
In addition to our MultiTAA therapies, we are
developing peptide-based immunotherapeutic vaccines that are designed to precisely target breast and ovarian cancer cells, in contrast
to standard therapies for the treatment of cancer that target both cancer cells and normal cells. We are currently evaluating TPIV100/110
for the treatment of breast cancers that overexpress human epidermal growth factor receptor 2 in a Phase 1b clinical trial and
TPIV200 for the treatment of breast and ovarian cancers that overexpress folate receptor alpha in multiple Phase 2 clinical trials,
including in ovarian cancer, for which we expect to report interim data in the fourth quarter of 2019, and triple negative breast
cancer, for which we recently reported that 26 of the 27 patients evaluated for immunogenicity showed significant immune response
to treatment as of March 2019. We believe that our peptide vaccines and our PolyStart technology, which is currently in preclinical
development, can be used as both standalone therapies and as complementary therapies that enhance the efficacy of other immunotherapy
approaches.
We believe that our therapies present promising
innovations in immuno-oncology. We developed our MultiTAA therapy in collaboration with the Cell and Gene Therapy Center at Baylor
College of Medicine, which was founded by Dr. Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in immuno-oncology. Baylor
College of Medicine remains an important strategic partner and conducts early-stage clinical trials of our MultiTAA therapies pursuant
to a sponsored research agreement. Our cell therapy founders include Drs. Brenner, Ann Leen, Ph.D., Juan Vera, M.D., Helen Heslop,
M.D., DSc (Hon) and Cliona Rooney, Ph.D., who all have significant experience in this field. Drs. Brenner, Heslop, Rooney, James
P. Allison and Padmanee Sharma serve on our Scientific Advisory Board.
Pipeline
Our clinical-stage pipeline, including clinical
trials being conducted by Baylor College of Medicine, is set forth below.
MAPP: autologous
LAPP: allogeneic
Corporate Information
We were incorporated under the laws of the
State of Nevada in 1991 under the name “TapImmune, Inc.” and reincorporated in Delaware in October 2018 under the name
“Marker Therapeutics, Inc.” On October 17, 2018, we completed a business combination with a Delaware corporation that
was then known as “Marker Therapeutics, Inc.,” or Private Marker, in accordance with the terms of the Agreement
and Plan of Merger and Reorganization dated as of May 15, 2018, or the Merger Agreement, by and among us, Private Marker and Timberwolf
Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of TapImmune, or Merger Sub, pursuant to which, among
other matters, Merger Sub merged with and into Private Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune
and the surviving corporation of the merger. In connection with the merger, we changed our name from “TapImmune, Inc.”
to “Marker Therapeutics, Inc.” and Private Marker changed its name to “Marker Cell Therapy, Inc.”
and became our wholly owned subsidiary. Our principal executive offices are located at 3200 Southwest Freeway, Suite 2240, Houston,
Texas 77027, and our telephone number is (713) 400-6400. Our website is located at http://www.markertherapeutics.com. We
do not incorporate by reference into this prospectus the information on, or accessible through, our website, and you should not
consider it as part of this prospectus.
The Securities We May Offer
We may offer shares of our common stock and
preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in
combination, up to a total aggregate offering price of $200,000,000 from time to time in one or more offerings under this prospectus,
together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined
by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities
we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement
that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:
|
·
|
designation or classification;
|
|
·
|
aggregate principal amount or aggregate offering price;
|
|
·
|
original issue discount, if any;
|
|
·
|
rates and times of payment of interest or dividends, if any;
|
|
·
|
redemption, conversion, exchange or sinking fund terms, if any;
|
|
·
|
conversion or exchange prices or rates, if any, and, if applicable,
any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property
receivable upon conversion or exchange;
|
|
·
|
restrictive covenants, if any;
|
|
·
|
voting or other rights, if any; and
|
|
·
|
important U.S. federal income tax considerations.
|
The applicable prospectus supplement and any
related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained
in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus
will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration
statement of which this prospectus is a part.
This prospectus may not be used to consummate
a sale of securities unless it is accompanied by a prospectus supplement.
We may sell the securities directly to investors
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part
of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable
prospectus supplement:
|
·
|
the names of those underwriters or agents;
|
|
·
|
applicable fees, discounts and commissions to be paid to them;
|
|
·
|
details regarding over-allotment options, if any; and
|
|
·
|
the estimated net proceeds to us.
|
Common Stock. We may issue shares
of our common stock from time to time. Holders of our common stock are entitled to one vote for each share held on all matters
submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall
be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are
entitled to receive ratably any dividends as may be declared by our board of directors, subject to any preferential dividend rights
of any series of preferred stock that we may designate and issue in the future.
In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to receive ratably our net assets available for distribution to stockholders
after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders
of common stock have no preemptive, subscription, redemption or conversion rights. There are no redemption or sinking fund provisions
applicable to the common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.
Preferred Stock. We may issue
shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors
has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock, par value $0.001
per share. You should refer to our certificate of incorporation and our bylaws, both of which are included as exhibits to the registration
statement of which this prospectus is a part.
Our board of directors
may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series
and may, at the time of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend
rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of preferred
stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares
of preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of
our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares
of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control
by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of
directors, without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely
affect the holders of shares of our common stock.
If we offer a specific
series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement
for such offering and will file a copy of the certificate of designation establishing the terms of the preferred stock with
the SEC. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be
provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that
contains the terms of the applicable series of preferred stock.
Debt Securities. We may issue
debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible
debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities
will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt,
to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or
other securities. Conversion may be mandatory or at the holder’s option and would be at prescribed conversion rates.
Any debt securities issued under this prospectus
will be issued under one or more documents called indentures, which are contracts between us and a national banking association
or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We
urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided
to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the
debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part,
and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed
as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports
that we file with the SEC.
Warrants. We may issue
warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants
independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate
from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to
read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related
to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain
the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants
that may be offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental
warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus
is a part or will be incorporated by reference from reports that we file with the SEC before the issuance of such warrants.
Any warrants issued under this prospectus will
be evidenced by warrant certificates. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant
agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the
particular series of warrants being offered.
RISK FACTORS
Investing in our securities involves a high
degree of risk. You should carefully review the risks and uncertainties described under the heading “Risk Factors”
contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual
Report on Form 10-K for the year ended December 31, 2018, as updated by any subsequently filed periodic reports and other
documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being
registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors described in the
documents referenced above could adversely affect our business, operating results and financial condition, as well as adversely
affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part
of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly
impair our business operations.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated
by reference herein contain forward-looking statements. These are based on our management’s current beliefs, expectations
and assumptions about future events, conditions and results and on information currently available to us. Discussions containing
these forward-looking statements may be found, among other places, in the sections entitled “Business,” “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained
in the documents incorporated by reference herein.
Any statements in this prospectus, or incorporated
herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts
and are forward-looking statements. Within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, these forward-looking statements include statements regarding:
|
·
|
the timing, progress and results of clinical trials of our MultiTAA
therapies and other product candidates, including statements regarding the timing of initiation and completion of preclinical studies
or clinical trials or related preparatory work, the period during which the results of the trials will become available and our
research and development programs;
|
|
·
|
the timing of any submission of filings for regulatory approval of
our product candidates and our ability to obtain and maintain regulatory approvals for our product candidates for any indication;
|
|
·
|
our expectations regarding the potential benefits, activity, effectiveness
and safety of our product candidates;
|
|
·
|
our expectations regarding the size of the patient populations, market
acceptance and opportunity for and clinical utility of our product candidates, if approved for commercial use;
|
|
·
|
our manufacturing capabilities and strategy, including the, ease,
scalability and commercial viability of our manufacturing methods and processes;
|
|
·
|
our expectations regarding the scope of any approved indications for
our product candidates;
|
|
·
|
our ability to successfully commercialize our product candidates;
|
|
·
|
the potential benefits of and our ability to maintain our relationships
and collaborations with the Baylor College of Medicine and other potential collaboration or strategic relationships;
|
|
·
|
our ability to use our MultiTAA platform to develop future product
candidates;
|
|
·
|
our estimates of our expenses, ongoing losses, future revenue, capital
requirements and our needs for or ability to obtain additional funding;
|
|
·
|
our ability to identify, recruit and retain key personnel;
|
|
·
|
our ability to protect and enforce our intellectual property position
for our product candidates, and the scope of such protection;
|
|
·
|
our financial performance;
|
|
·
|
our competitive position and the development of and projections relating
to our competitors or our industry; and
|
|
·
|
the impact of laws and regulations.
|
In some cases, you can identify forward-looking
statements by the words “may,” “might,” “can,” “will,” “to be,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,”
“likely,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology
intended to identify statements about the future, although not all forward-looking statements contain these words. These statements
involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements.
You should refer to the “Risk Factors”
section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in
the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause
our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties
and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus
will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking
statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve
our objectives and plans in any specified time frame, or at all.
Except as required by law, we assume no obligation
to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments
occurring after the date of this prospectus, even if new information becomes available in the future.
USE OF PROCEEDS
We will retain broad discretion over the use
of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement
or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently
intend to use the net proceeds from the sale of the securities offered hereby for working capital, capital expenditures and general
corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that
we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions
as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our
intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing
prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities.
DESCRIPTION OF CAPITAL STOCK
The following description of our capital
stock and provisions of our certificate of incorporation and bylaws are summaries. You should also refer to the certificate of
incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.
General
Our certificate of incorporation authorizes
us to issue up to 150,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share. Our board of directors may establish the rights and preferences of the preferred stock from time to time.
As of March 31, 2019, we had outstanding 45,484,483 shares of common stock and no shares of preferred stock outstanding.
Common Stock
Voting Rights
Holders of our common stock are entitled to
one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. As a
result, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of
the directors standing for election, if they should so choose.
Dividends
Holders of common stock are entitled to receive
ratably any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of
preferred stock that we may designate and issue in the future.
Liquidation
In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to receive ratably our net assets available for distribution to stockholders
after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.
Rights and Preferences
Holders of common stock have no preemptive,
subscription, redemption or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock.
The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of
the holders of shares of any series of preferred stock that we may designate and issue in the future.
Preferred Stock
Pursuant to our certificate of incorporation,
our board of directors has the authority, without further action by our stockholders, from time to time, to designate and issue
up to 5,000,000 shares of preferred stock in one or more series. Our board of directors may determine the rights, preferences and
limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of
any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of
dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment in
the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our
common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to discourage
a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal
of incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval, we may issue shares
of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock.
Our board of directors will fix the designations,
voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the
preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of
designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is
a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that
describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This
description will include:
|
·
|
the title and stated value;
|
|
·
|
the number of shares we are offering;
|
|
·
|
the liquidation preference per share;
|
|
·
|
the purchase price per share;
|
|
·
|
the dividend rate per share, dividend period and payment dates and
method of calculation for dividends;
|
|
·
|
whether dividends will be cumulative or non-cumulative and, if cumulative,
the date from which dividends will accumulate;
|
|
·
|
our right, if any, to defer payment of dividends and the maximum length
of any such deferral period;
|
|
·
|
the procedures for any auction and remarketing, if any;
|
|
·
|
the provisions for a sinking fund, if any;
|
|
·
|
the provisions for redemption or repurchase, if applicable, and any
restrictions on our ability to exercise those redemption and repurchase rights;
|
|
·
|
any listing of the preferred stock on any securities exchange or market;
|
|
·
|
whether the preferred stock will be convertible into our common stock
or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion
price, or how it will be calculated, and under what circumstances it may be adjusted;
|
|
·
|
whether the preferred stock will be exchangeable into debt securities,
and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may
be adjusted;
|
|
·
|
voting rights, if any, of the preferred stock;
|
|
·
|
preemption rights, if any;
|
|
·
|
restrictions on transfer, sale or other assignment, if any;
|
|
·
|
whether interests in the preferred stock will be represented by depositary
shares;
|
|
·
|
a discussion of any material or special U.S. federal income tax considerations
applicable to the preferred stock;
|
|
·
|
the relative ranking and preferences of the preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our affairs;
|
|
·
|
any limitations on issuances of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; and
|
|
·
|
any other specific terms, rights, preferences, privileges, qualifications
or restrictions of the preferred stock.
|
The General Corporation Law of the State of
Delaware, or DGCL, the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately
as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the
par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class or change
the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may
be. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.
The issuance of preferred stock could adversely
affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments
and payments upon liquidation. The issuance could have the effect of decreasing the market price of the common stock. The issuance
of preferred stock also could have the effect of delaying, deterring or preventing a change in control of us.
Anti-Takeover Provisions
Section 203
of the Delaware General Corporation Law
We are subject to Section 203 of the DGCL,
which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of
three years after the date that such stockholder became an interested stockholder, with the following exceptions:
|
·
|
before such date, the board of directors of the corporation approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder;
|
|
·
|
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes
of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares
owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange
offer; or
|
|
·
|
on or after such date, the business combination is approved by the board of directors and authorized at an annual or special
meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
stock that is not owned by the interested stockholder.
|
In general, Section 203 defines a "business
combination" to include the following:
|
·
|
any merger or consolidation involving the corporation and the interested stockholder;
|
|
·
|
any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;
|
|
·
|
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of
the corporation to the interested stockholder;
|
|
·
|
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class
or series of the corporation beneficially owned by the interested stockholder; or
|
|
·
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
by or through the corporation.
|
In general, Section 203 defines an "interested
stockholder" as an entity or person who, together with the person's affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting
stock of the corporation.
Certificate of Incorporation and Bylaws
Because our stockholders do not have cumulative
voting rights, stockholders holding a plurality of the shares of our common stock outstanding will be able to elect all of our
directors. Our bylaws also provide that directors may be removed by the stockholders upon the vote of a majority of the shares
entitled to vote an election of directors, and if a director was elected by a voting group of stockholders, only stockholders from
that voting group may vote to remove such director, and such vacancy may be filled only by the stockholders of that voting group.
Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and
newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only
be filled by a majority vote of the directors then serving on the board, even though less than a quorum.
Our bylaws provide that only a majority of
the authorized directors on our board of directors, the chairman of the board or the chief executive officer to call a special
meeting of stockholders. Our bylaws also provide that stockholders seeking to present proposals before a meeting of stockholders
to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and
specify requirements as to the form and content of a stockholder's notice.
The combination of these provisions may make
it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control
of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these
provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition,
the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting
or other rights or preferences that could impede the success of any attempt to change our control.
These provisions are intended to enhance the
likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover
practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and
to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging
others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a
consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored
takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages
of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.
Transfer Agent and Registrar
The transfer agent and registrar for our common
stock is Island Stock Transfer, with offices at 15500 Roosevelt Boulevard, Clearwater, FL 33760. The transfer agent for any series
of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.
Listing on Nasdaq
Our common stock is listed on the Nasdaq Capital
Market under the symbol “MRKR.”
DESCRIPTION OF DEBT SECURITIES
We may issue debt securities from time to time,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we
have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the
particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of
any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires
otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a
particular series of debt securities.
We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture
Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement
of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities
being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated
by reference from reports that we file with the SEC.
The following summary of material provisions
of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of
the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and
any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete
indenture that contains the terms of the debt securities.
General
The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and
may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of
all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other
provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or
transactions involving us.
We may issue the debt securities issued under
the indenture as “discount securities,” which means they may be sold at a discount below their stated principal amount.
These debt securities, as well as other debt securities that are not issued at a discount, may be issued with “original issue
discount,” or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of
the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described
in more detail in any applicable prospectus supplement.
We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:
|
·
|
the title of the series of debt securities;
|
|
·
|
any limit upon the aggregate principal amount that may be issued;
|
|
·
|
the maturity date or dates;
|
|
·
|
the form of the debt securities of the series;
|
|
·
|
the applicability of any guarantees;
|
|
·
|
whether or not the debt securities will be secured or unsecured, and
the terms of any secured debt;
|
|
·
|
whether the debt securities rank as senior debt, senior subordinated
debt, subordinated debt or any combination thereof, and the terms of any subordination;
|
|
·
|
if the price (expressed as a percentage of the aggregate principal
amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of
the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of
the principal amount of such debt securities that is convertible into another security or the method by which any such portion
shall be determined;
|
|
·
|
the interest rate or rates, which may be fixed or variable, or the
method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for determining such dates;
|
|
·
|
our right, if any, to defer payment of interest and the maximum length
of any such deferral period;
|
|
·
|
if applicable, the date or dates after which, or the period or periods
during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional
or provisional redemption provisions and the terms of those redemption provisions;
|
|
·
|
the date or dates, if any, on which, and the price or prices at which
we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s
option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;
|
|
·
|
the denominations in which we will issue the series of debt securities,
if other than denominations of $1,000 and any integral multiple thereof;
|
|
·
|
any and all terms, if applicable, relating to any auction or remarketing
of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms
which may be advisable in connection with the marketing of debt securities of that series;
|
|
·
|
whether the debt securities of the series shall be issued in whole
or in part in the form of a global security or securities;
|
|
·
|
the terms and conditions, if any, upon which such global security
or securities may be exchanged in whole or in part for other individual securities;
|
|
·
|
the depositary for such global security or securities;
|
|
·
|
if applicable, the provisions relating to conversion or exchange of
any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable,
including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional
(at our option or the holders’ option) conversion or exchange features, the applicable conversion or exchange period and
the manner of settlement for any conversion or exchange;
|
|
·
|
if other than the full principal amount thereof, the portion of the
principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof;
|
|
·
|
additions to or changes in the covenants applicable to the particular
debt securities being issued, including, among others, the consolidation, merger or sale covenant;
|
|
·
|
additions to or changes in the events of default with respect to the
securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if
any, with respect to such securities to be due and payable;
|
|
·
|
additions to or changes in or deletions of the provisions relating
to covenant defeasance and legal defeasance;
|
|
·
|
additions to or changes in the provisions relating to satisfaction
and discharge of the indenture;
|
|
·
|
additions to or changes in the provisions relating to the modification
of the indenture both with and without the consent of holders of debt securities issued under the indenture;
|
|
·
|
the currency of payment of debt securities if other than U.S. dollars
and the manner of determining the equivalent amount in U.S. dollars;
|
|
·
|
whether interest will be payable in cash or additional debt securities
at our or the holders’ option and the terms and conditions upon which the election may be made;
|
|
·
|
the terms and conditions, if any, upon which we will pay amounts in
addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that
is not a “United States person” for federal tax purposes;
|
|
·
|
any restrictions on transfer, sale or assignment of the debt securities
of the series; and
|
|
·
|
any other specific terms, preferences, rights or limitations of, or
restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may
be required by us or advisable under applicable laws or regulations.
|
Conversion or Exchange Rights
We will set forth in the applicable prospectus
supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other
securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory,
at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock
or our other securities that the holders of the series of debt securities receive would be subject to adjustment.
Consolidation, Merger or Sale
Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as
an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations
under the indenture or the debt securities, as appropriate.
Events of Default under the Indenture
Unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect
to any series of debt securities that we may issue:
|
·
|
if we fail to pay any installment of interest on any series of debt
securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however,
that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall
not constitute a default in the payment of interest for this purpose;
|
|
·
|
if we fail to pay the principal of, or premium, if any, on any series
of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise,
or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a
valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall
not constitute a default in the payment of principal or premium, if any;
|
|
·
|
if we fail to observe or perform any other covenant or agreement contained
in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and
our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating
that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding
debt securities of the applicable series; and
|
|
·
|
if specified events of bankruptcy, insolvency or reorganization occur.
|
If an event of default with respect to debt
securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the
trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice
to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any,
and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs
with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall
be due and payable without any notice or other action on the part of the trustee or any holder.
The holders of a majority in principal amount
of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and
its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we
have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.
Subject to the terms of the indenture, if an
event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding
debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that
series, provided that:
|
·
|
the direction so given by the holder is not in conflict with any law
or the applicable indenture; and
|
|
·
|
subject to its duties under the Trust Indenture Act, the trustee need
not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the
proceeding.
|
A holder of the debt securities of any series
will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies
only if:
|
·
|
the holder has given written notice to the trustee of a continuing
event of default with respect to that series;
|
|
·
|
the holders of at least 25% in aggregate principal amount of the outstanding
debt securities of that series have made written request,
|
|
·
|
such holders have offered to the trustee indemnity satisfactory to
it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and
|
|
·
|
the trustee does not institute the proceeding, and does not receive
from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting
directions within 90 days after the notice, request and offer.
|
These limitations do not apply to a suit instituted
by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.
We will periodically file statements with the
trustee regarding our compliance with specified covenants in the indenture.
Modification of Indenture; Waiver
We and the trustee may change an indenture without
the consent of any holders with respect to specific matters:
|
·
|
to cure any ambiguity, defect or inconsistency in the indenture or
in the debt securities of any series;
|
|
·
|
to comply with the provisions described above under “Description
of Debt Securities—Consolidation, Merger or Sale;”
|
|
·
|
to provide for uncertificated debt securities in addition to or in
place of certificated debt securities;
|
|
·
|
to add to our covenants, restrictions, conditions or provisions such
new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to
make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions
or provisions an event of default or to surrender any right or power conferred upon us in the indenture;
|
|
·
|
to add to, delete from or revise the conditions, limitations, and
restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth
in the indenture;
|
|
·
|
to make any change that does not adversely affect the interests of
any holder of debt securities of any series in any material respect;
|
|
·
|
to provide for the issuance of and establish the form and terms and
conditions of the debt securities of any series as provided above under “Description of Debt Securities—General”
to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt
securities, or to add to the rights of the holders of any series of debt securities;
|
|
·
|
to evidence and provide for the acceptance of appointment under any
indenture by a successor trustee; or
|
|
·
|
to comply with any requirements of the SEC in connection with the
qualification of any indenture under the Trust Indenture Act.
|
In addition, under the indenture, the rights
of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least
a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make
the following changes only with the consent of each holder of any outstanding debt securities affected:
|
·
|
extending the fixed maturity of any debt securities of any series;
|
|
·
|
reducing the principal amount, reducing the rate of or extending the
time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or
|
|
·
|
reducing the percentage of debt securities, the holders of which are
required to consent to any amendment, supplement, modification or waiver.
|
Discharge
Each indenture provides that we can elect
to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations,
including obligations to:
|
·
|
register the transfer or exchange of debt securities of the series;
|
|
·
|
replace stolen, lost or mutilated debt securities of the series;
|
|
·
|
pay principal of and premium and interest on any debt securities of
the series;
|
|
·
|
maintain paying agencies;
|
|
·
|
hold monies for payment in trust;
|
|
·
|
recover excess money held by the trustee;
|
|
·
|
compensate and indemnify the trustee; and
|
|
·
|
appoint any successor trustee.
|
In order to exercise our rights to be discharged,
we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and
interest on, the debt securities of the series on the dates payments are due.
Form, Exchange and Transfer
We will issue the debt securities of each
series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement,
in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series
in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository
Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to
that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms
relating to any book-entry securities will be set forth in the applicable prospectus supplement.
At the option of the holder, subject to
the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement,
the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series,
in any authorized denomination and of like tenor and aggregate principal amount.
Subject to the terms of the indenture and
the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities
may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office
of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents
for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment
of any taxes or other governmental charges.
We will name in the applicable prospectus
supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for
any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent
in each place of payment for the debt securities of each series.
If we elect to redeem the debt securities
of any series, we will not be required to:
|
·
|
issue, register the transfer of, or exchange any debt securities of
that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption
of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or
|
|
·
|
register the transfer of or exchange any debt securities so selected
for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.
|
Information Concerning the Trustee
The trustee, other than during the occurrence
and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth
in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent
person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation
to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable
security and indemnity against the costs, expenses and liabilities that it might incur.
Payment and Paying Agents
Unless we otherwise indicate in the applicable
prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.
We will pay principal of and any premium
and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless
we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the
holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series.
We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities
of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.
All money we pay to a paying agent or the
trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end
of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt
security thereafter may look only to us for payment thereof.
Governing Law
The indenture and the debt securities will
be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.
DESCRIPTION OF WARRANTS
The following description, together with
the additional information we may include in any applicable prospectus supplement and in any related free writing prospectuses,
summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants
to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently
or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to
or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer
under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the
applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus
supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that
are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its
effectiveness.
We have filed forms of the warrant agreements
and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement
of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part,
or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form
of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries
of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference
to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we
may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of
warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements
and warrant certificates that contain the terms of the warrants.
General
We will describe in the applicable prospectus
supplement the terms relating to a series of warrants being offered, including, to the extent applicable:
|
·
|
the title of such securities;
|
|
·
|
the offering price or prices and aggregate number of warrants offered;
|
|
·
|
the currency or currencies for which the warrants may be purchased;
|
|
·
|
if applicable, the designation and terms of the securities with which
the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;
|
|
·
|
if applicable, the date on and after which the warrants and the related
securities will be separately transferable;
|
|
·
|
if applicable, the minimum or maximum amount of such warrants which
may be exercised at any one time;
|
|
·
|
in the case of warrants to purchase debt securities, the principal
amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal
amount of debt securities may be purchased upon such exercise;
|
|
·
|
in the case of warrants to purchase common stock or preferred stock,
the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the
price at which, and the currency in which, these shares may be purchased upon such exercise;
|
|
·
|
the effect of any merger, consolidation, sale or other disposition
of our business on the warrant agreements and the warrants;
|
|
·
|
the terms of any rights to redeem or call the warrants;
|
|
·
|
the terms of any rights to force the exercise of the warrants;
|
|
·
|
any provisions for changes to or adjustments in the exercise price
or number of securities issuable upon exercise of the warrants;
|
|
·
|
the dates on which the right to exercise the warrants will commence
and expire;
|
|
·
|
the manner in which the warrant agreements and warrants may be modified;
|
|
·
|
a discussion of any material or special U.S. federal income tax consequences
of holding or exercising the warrants;
|
|
·
|
the terms of the securities issuable upon exercise of the warrants;
and
|
|
·
|
any other specific terms, preferences, rights or limitations of or
restrictions on the warrants.
|
Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:
|
·
|
in the case of warrants to purchase debt securities, the right to
receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce
covenants in the applicable indenture; or
|
|
·
|
in the case of warrants to purchase common stock or preferred stock,
the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights,
if any.
|
Exercise of Warrants
Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become void.
Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the
warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately
available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate
and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant
agent in connection with the exercise of the warrant.
Upon receipt of the required payment and
the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate
for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender
securities as all or part of the exercise price for warrants.
Governing Law
Unless we provide otherwise in the applicable
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the
warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York.
Enforceability of Rights by Holders of Warrants
Each warrant agent will act solely as our
agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right
to exercise, and receive the securities purchasable upon exercise of, its warrants.
LEGAL OWNERSHIP OF SECURITIES
We can issue securities in registered form
or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons
who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain
for this purpose as the “holders” of those securities. These persons are the legal holders of the securities. We refer
to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names,
as “indirect holders” of those securities. As we discuss below, indirect holders are not legal holders, and investors
in securities issued in book-entry form or in street name will be indirect holders.
Book-Entry Holders
We may issue securities in book-entry form
only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global
securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions
that participate in the depositary’s book-entry system. These participating institutions, which are referred to as participants,
in turn, hold beneficial interests in the securities on behalf of themselves or their customers.
Only the person in whose name a security
is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary
or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities,
and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its
participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants
do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms
of the securities.
As a result, investors in a global security
will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other
financial institution that participates in the depositary’s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.
Street Name Holders
We may terminate a global security or issue
securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names
or in “street name.” Securities held by an investor in street name would be registered in the name of a bank, broker
or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities
through an account he or she maintains at that institution.
For securities held in street name, we
or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in
whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make
all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the
beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do
so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.
Legal Holders
Our obligations, as well as the obligations
of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not
have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means.
This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing
the securities only in global form.
For example, once we make a payment or
give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under
agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly,
we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our
obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval
only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect
holders is up to the legal holders.
Special Considerations for Indirect Holders
If you hold securities through a bank,
broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities
or in street name, you should check with your own institution to find out:
|
·
|
how it handles securities payments and notices;
|
|
·
|
whether it imposes fees or charges;
|
|
·
|
how it would handle a request for the holders’ consent, if ever
required;
|
|
·
|
whether and how you can instruct it to send you securities registered
in your own name so you can be a holder, if that is permitted in the future;
|
|
·
|
how it would exercise rights under the securities if there were a
default or other event triggering the need for holders to act to protect their interests; and
|
|
·
|
if the securities are in book-entry form, how the depositary’s
rules and procedures will affect these matters.
|
Global Securities
A global security is a security that represents
one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global
securities will have the same terms.
Each security issued in book-entry form
will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or
its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the
depositary for all securities issued in book-entry form.
A global security may not be transferred
to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination
situations arise. We describe those situations below under “—Special Situations When a Global Security Will Be Terminated.”
As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities
represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with
the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will
not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.
If the prospectus supplement for a particular
security indicates that the security will be issued as a global security, then the security will be represented by a global security
at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.
Special Considerations for Global Securities
As an indirect holder, an investor’s
rights relating to a global security will be governed by the account rules of the investor’s financial institution and of
the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.
If securities are issued only as global
securities, an investor should be aware of the following:
|
·
|
an investor cannot cause the securities to be registered in his or
her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations
we describe below;
|
|
·
|
an investor will be an indirect holder and must look to his or her
own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe
above;
|
|
·
|
an investor may not be able to sell interests in the securities to
some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form;
|
|
·
|
an investor may not be able to pledge his or her interest in the global
security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of
the pledge in order for the pledge to be effective;
|
|
·
|
the depositary’s policies, which may change from time to time,
will govern payments, transfers, exchanges and other matters relating to an investor’s interest in the global security;
|
|
·
|
we and any applicable trustee have no responsibility for any aspect
of the depositary’s actions or for its records of ownership interests in the global security, nor will we or any applicable
trustee supervise the depositary in any way;
|
|
·
|
the depositary may, and we understand that DTC will, require that
those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and
your broker or bank may require you to do so as well; and
|
|
·
|
financial institutions that participate in the depositary’s
book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting
payments, notices and other matters relating to the securities.
|
There may be more than one financial intermediary
in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.
Special Situations When a Global Security Will Be Terminated
In a few special situations described below,
a global security will terminate and interests in it will be exchanged for physical certificates representing those interests.
After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors
must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so
that they will be direct holders. We have described the rights of holders and street name investors above.
Unless we provide otherwise in the applicable
prospectus supplement, a global security will terminate when the following special situations occur:
|
·
|
if the depositary notifies us that it is unwilling, unable or no longer
qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within
90 days;
|
|
·
|
if we notify any applicable trustee that we wish to terminate that
global security; or
|
|
·
|
if an event of default has occurred with regard to securities represented
by that global security and has not been cured or waived.
|
The applicable prospectus supplement may
also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee,
is responsible for deciding the names of the institutions that will be the initial direct holders.
PLAN OF DISTRIBUTION
We may sell the securities from time to
time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may
sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
securities from time to time in one or more transactions:
|
·
|
at a fixed price or prices, which may be changed;
|
|
·
|
at market prices prevailing at the time of sale;
|
|
·
|
at prices related to such prevailing market prices; or
|
We may also sell equity securities covered
by this registration statement in an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act.
Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or
through the facilities of the Nasdaq Capital Market or any other securities exchange or quotation or trading service on which such
securities may be listed, quoted or traded at the time of sale. Such at the market offerings, if any, may be conducted by underwriters
acting as principal or agent.
A prospectus supplement or supplements
(and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of
the securities, including, to the extent applicable:
|
·
|
the name or names of any underwriters, dealers or agents, if any;
|
|
·
|
the purchase price of the securities and the proceeds we will receive
from the sale;
|
|
·
|
any over-allotment options under which underwriters may purchase additional
securities from us;
|
|
·
|
any agency fees or underwriting discounts and other items constituting
agents’ or underwriters’ compensation;
|
|
·
|
any public offering price;
|
|
·
|
any discounts or concessions allowed or reallowed or paid to dealers;
and
|
|
·
|
any securities exchange or market on which the securities may be listed.
|
Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.
If underwriters are used in the sale, they
will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at
a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities
to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement,
other than securities covered by any overallotment or other option. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship.
We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
We may sell securities directly or through
agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe
any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent
will act on a best-efforts basis for the period of its appointment.
We may authorize agents or underwriters
to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts
in the prospectus supplement.
We may provide agents and underwriters
with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution
with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may
engage in transactions with, or perform services for, us in the ordinary course of business.
All securities we may offer, other than
common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee
the liquidity of the trading markets for any securities.
Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing
bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after
the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from
a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters
may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market
or otherwise.
Any underwriters or agents who are qualified
market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital
Market in accordance with Rule 103 of Regulation M under the Exchange Act, during the business day prior to the pricing of the
offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume
and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid
at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive
market maker’s bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.
Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the
open market and, if commenced, may be discontinued at any time.
In compliance with guidelines of the Financial
Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent
broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.
LEGAL MATTERS
Unless otherwise indicated in the applicable
prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this
prospectus, and any supplement thereto, will be passed upon by Cooley LLP, New York, New York. Additional legal matters may be
passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
EXPERTS
Marcum LLP, independent registered
public accounting firm, has audited our consolidated financial statements as of and for the years ended December 31, 2018 and
2017 and the effectiveness of our internal control over financial reporting as of December 31, 2018 as set forth in its reports,
which are included in our 2018 Annual Report on Form 10-K and incorporated by reference in this prospectus and
elsewhere in the registration statement. Our 2018 and 2017 financial statements are incorporated by reference in reliance on
Marcum LLP’s report, given on their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus is part of a registration
statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement
and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under
this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration
statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus.
We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in
any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any
date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale
of the securities offered by this prospectus.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at
http://www.sec.gov.
Copies of certain information filed by
us with the SEC are also available on our website at http://www.markertherapeutics.com. Information contained in or accessible
through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus.
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
The SEC allows us to “incorporate
by reference” information into this prospectus, which means that we can disclose important information to you by referring
you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this
prospectus is 001-37939. The documents incorporated by reference into this prospectus contain important information that you should
read about us.
The following documents are incorporated
by reference into this document:
|
·
|
our Annual Report on Form 10-K for the fiscal year ended December
31, 2018, filed with the SEC on March 15, 2019;
|
|
·
|
the information specifically incorporated by reference into our Annual
Report on Form 10-K for the year ended December 31, 2018 from our Definitive Proxy Statement on Schedule 14A, filed with the SEC
on March 28, 2019;
|
|
·
|
our Quarterly Report on Form 10-Q for the fiscal quarter ended March
31, 2019, filed with the SEC on May 10, 2019;
|
|
·
|
our Current Reports on Form 8-K filed with the SEC on January 4, 2019,
January 15, 2019, February 15, 2019, February 25, 2019, March 28, 2019, April 17, 2019 and May 10, 2019; and
|
|
·
|
the description of our common stock set forth in the registration
statement on Form 8-A registering our common stock under Section 12 of the Exchange Act, which was filed with the SEC on November 3, 2016, including any amendments or reports filed for purposes of updating such description.
|
We also incorporate by reference into this
prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such
form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness
of the registration statement, or (ii) after the date of this prospectus but prior to the termination of the offering. These documents
include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
as well as proxy statements.
We will provide to each person, including
any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the
documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that
are specifically incorporated by reference into such documents. You should direct any requests for documents to Marker Therapeutics, Inc.,
Attn: Corporate Secretary, 3200 Southwest Freeway, Suite 2240, Houston, Texas 77027.
Any statement contained in this prospectus
or contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified
or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus,
or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement.
$
MARKER THERAPEUTICS, INC.
Common Stock
PROSPECTUS SUPPLEMENT
Piper
Sandler
,
2021
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024